Skip to main content

Summit Therapeutics PLC (SMMT) Stock

Summit Therapeutics PLC Stock Details, Movements and Public Alerts

Stock Details

Summit Therapeutics PLC (SMMT), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $13.78. Over the past 52 weeks, it has ranged between $12.07 and $29.23. This places the current price at 47.1% of its 52-week high and 14.2% above its 52-week low. Recent trading volume was recorded at 6,333,610. The 14-day Relative Strength Index (RSI) stands at 47.57, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $14.08 by 2.13%. Similarly, it is below its 200-day moving average of $16.54 by 16.69%. The MACD histogram is -0.04, indicating bearish momentum (MACD Line: -0.35, Signal Line: -0.31). There are currently 2 active alerts set for SMMT by users.

52-Week Range

$29.23 - $12.07

-52.86% from high · +14.17% from low

Avg Daily Volume

4,975,643

20-day average

100-day avg: 4,990,076

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

3.72

PEG Ratio

0.00

Potentially undervalued

Price to Book

16.65

EV/EBITDA

-5.32

EPS (TTM)

-$1.11

Price to Sales

3891.31

Beta

-1.24

Less volatile than market

Q:How is SMMT valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is SMMT's risk profile compared to the market?
With a beta of -1.24, Summit Therapeutics PLC is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 16.65 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-874,670,016

Return on Equity

-192.50%

Return on Assets

-101.60%

Revenue Growth (YoY)

-100.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is SMMT's business model?
Profitability metrics are not available for this stock.
Q:What are SMMT's recent growth trends?
Summit Therapeutics PLC's revenue declined by 100.00% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$10.2B

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

797.75M

Book Value/Share

$0.79

Asset Type

Common Stock

Q:What is SMMT's market capitalization and position?
Summit Therapeutics PLC has a market capitalization of $10.2B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 797.75M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does SMMT's price compare to its book value?
Summit Therapeutics PLC's book value per share is $0.79, while the current stock price is $13.78, resulting in a price-to-book (P/B) ratio of 17.36. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$28.63

107.76% upside potential

Analyst Recommendations

Strong Buy

1

Buy

9

Hold

5

Sell

0

Strong Sell

2

Q:How reliable are analyst predictions for SMMT?
17 analysts cover SMMT with 59% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $28.63 implies 107.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on SMMT?
Current analyst recommendations:1 Strong Buy, 9 Buy, 5 Hold, 02 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 26, 2026, 02:27 AM

Technical Indicators

RSI (14-day)

47.57

Neutral

50-Day Moving Average

$14.08

-2.13% below MA-50

200-Day Moving Average

$16.54

-16.69% below MA-200

MACD Line

-0.35

MACD Signal

-0.31

MACD Histogram

-0.04

Bearish

Q:What does SMMT's RSI value tell investors?
The RSI (Relative Strength Index) for SMMT is currently 47.57, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret SMMT's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.35 below the signal line at -0.31, with histogram at -0.04. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($14.08) is below the 200-day MA ($16.54), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Aug 26, 2026, 12:31 AM

Active Alerts

Alert Condition
Price falls below
Threshold
$11.55
Created
Aug 13, 2026, 03:39 PM
Alert Condition
Price falls below
Threshold
$11.55
Created
Aug 13, 2026, 03:23 PM

Stay Ahead of the Market with Summit Therapeutics PLC Alerts

Set up price alerts for Summit Therapeutics PLC and get notified instantly when the price hits your target. Never miss an important price movement again.